#USA #New York #Pomerantz LLP #Adverum Biotechnologies #ADVM

Investor Alert: Pomerantz Law Firm Investigates Adverum Biotechnologies

On April 28, 2025, Pomerantz LLP announced its investigation into potential claims regarding securities fraud against Adverum Biotechnologies, Inc. (NASDAQ: ADVM). This investigation is aimed at protecting the interests of investors who may have been affected by the company’s recent disclosures. If you are a shareholder of Adverum and have insights or claims related to these matters, the firm encourages you to contact Danielle Peyton at [email protected].

Background

On March 31, 2025, Adverum Biotechnologies made a crucial filing with the U.S. Securities and Exchange Commission. The company admitted to discrepancies involving its previously issued financial statements, specifically highlighting non-cash errors linked to tenant improvement allowances. These financial misstatements pertain to an operating lease and sublease concerning a facility located in North Carolina, designated as the 'NC Premises.'

Such errors have led Adverum to announce that they will be restating their financial statements for the years ending December 31, 2022, and 2023. Furthermore, the corrections will also reflect unaudited condensed consolidated quarterly financial information for the quarters of 2023 and 2024. This announcement sent ripples throughout the financial community, subsequently causing Adverum's stock to plunge by 12.36%, or $0.54, closing at $3.83 per share on April 1, 2025.

Legal Context

Investors have the right to know whether Adverum and its officers or directors engaged in securities fraud or any unlawful business practices. Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation. With an extensive background in these areas, the firm aims to champion the rights of investors who may have suffered due to corporate misconduct, fraudulent activities, or breaches of fiduciary duty. Since its establishment by Abraham L. Pomerantz, the firm has built a reputation for securing considerable monetary settlements for victims of such injustices.

As a noted expert in the field, Pomerantz notes that the pursuit of justice for clients is paramount. They utilize their expertise to navigate the complexities of securities laws and ensure that those responsible for fraudulent activities are held accountable. Their track record includes recovering immense damages for shareholders, further demonstrating their commitment to integrity and investor protection.

Next Steps for Investors

Affected investors of Adverum are encouraged to review their investment positions and consult legal representatives if they have concerns regarding their filings or the integrity of their investments. Pomerantz is actively inviting individuals who believe they may have been affected by these developments to reach out directly to their offices.

Contact Information

For additional details regarding this ongoing investigation or to voice your claims, contact:

• - Danielle Peyton

Pomerantz LLP
Email: [email protected]
Phone: 646-581-9980, ext. 7980

The inquiry into Adverum Biotechnologies serves as a reminder of the importance of transparency and accountability within publicly traded companies. As financial markets evolve, it becomes increasingly crucial for investors to remain vigilant and informed about their investments.